Patients with nasopharyngeal carcinoma, salivary gland or skin primaries
Nasopharyngeal carcinoma
Patient has disease of nasopharyngeal carcinoma histology
Nasopharyngeal or sinonasal carcinoma
Disease at the nasopharyngeal, sinus, oral cavity, or other sub-site not specified
EBV (+) nasopharyngeal carcinoma in the protocol treated tumor
Primary nasopharyngeal carcinoma
Documentation that the patient is a candidate for chemoradiation of their nasopharyngeal cancer by one of the study investigators
Primary tumor of the nasopharynx (nasopharyngeal carcinoma)
Nasopharyngeal primary site
Primary nasopharyngeal carcinoma
Patients with nasopharyngeal, paranasal sinus, skin, or unknown primary site disease
Patients with nasopharyngeal carcinoma
Patients with nasopharyngeal carcinoma
Patients with nasopharyngeal carcinoma, skin squamous cell carcinoma (SCC), and salivary gland carcinomas are not eligible
Prior nasopharyngeal cancer, salivary gland or sinus tumors.
Epstein-Barr virus-associated nasopharyngeal carcinoma basket:\r\n* None
Patients with nasopharyngeal carcinoma are not eligible
Nasopharyngeal primary site, if WHO type II or III (non-keratinizing)
AT THE TIME OF PROCUREMENT: Nasopharyngeal carcinoma in first or subsequent relapse or with primary refractory disease
AT THE TIME OF INFUSION: Nasopharyngeal carcinoma in first or subsequent relapse or with primary refractory disease
Nasopharyngeal, salivary gland, lip or sinonasal carcinoma
Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma
Nasopharyngeal cancer
Nasopharyngeal strictures
Nasopharyngeal cancer
Eligible disease(s)/stage(s): nasopharyngeal carcinoma, paranasal sinus cancers/any stage
Patients with paranasal sinus or nasopharyngeal carcinoma who are about to undergo radiation therapy; patients with paranasal sinus or nasopharyngeal carcinoma who have completed radiation therapy - months prior to enrollment who then show olfactory loss on a screening test (University of Pennsylvania Smell Identification Test [UPSIT]  score of  or  or lower out of , depending on female/male); both those patients undergoing chemotherapy and those who did not will be eligible, and this factor will be assessed as a possible confounder/contributor in a multi-regression analysis
Patients with sinusitis, obstruction of nasal passages, nasopharyngeal cancer, paranasal sinus malignancies, or any conditions in the nasopharyngeal anatomical area that may affect the absorption of fentanyl nasal spray
Patient with nasopharyngeal carcinoma
Nasal, paranasal sinus, or nasopharyngeal carcinoma, aside from WHO Type I and II (keratinizing, non-EBV positive) nasopharyngeal carcinoma which will be allowed.
All nasopharyngeal, paranasal sinus, salivary cancer, and thyroid malignancies
Primary nasopharyngeal carcinoma.
